GPRC5D×CD3 TCE
/ Integral Molecular
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
GPRC5D multispecific antibodies: Engineering for affinity, cross-species reactivity, and bi/trispecific engagement in multiple myeloma
(AACR 2026)
- "GPRC5D multispecific antibodies hold promise as potent and safe therapeutics for multiple myeloma. Through CDR-Scanning, we are advancing a new generation of GPRC5D antibodies with enhanced attributes, including affinity improvements, pH sensitivity, reduced polyreactivity, improved half-life, and cross-reactivity in cynomolgus for preclinical development."
IO biomarker • Trispecific • Hematological Malignancies • Multiple Myeloma • Oncology
1 to 1
Of
1
Go to page
1